secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001193125-23-283679
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for reproxalap NDA in dry eye disease; additional trial required
--------------------------------------------------------------------------------

- FDA CRL states NDA did not demonstrate efficacy on ocular symptoms; requires at least one additional adequate and well-controlled study.
- No safety or manufacturing issues identified.
- Aldeyra submitted SPA for chamber crossover trial on Nov 16; expects FDA feedback in Dec 2023.
- Proposed trial cost <$2M, top-line results expected H1 2024; potential NDA resubmission in H1 2024.
- Cash runway extended to late 2025, with $143M cash as of Sep 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312523283679/0001193125-23-283679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312523283679/d723036d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-283679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer